Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Ipilimumab + Sargramostim + UV1 Telomerase peptide vaccine|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Ipilimumab||Yervoy||BMS-734016||CTLA4 Antibody 18 Immune Checkpoint Inhibitor 98||Yervoy (ipilimumab) is an antibody that binds to cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4), causing increased T-cell activation (PMID: 28891423). Yervoy (ipilimumab) is FDA approved for use in patients with metastatic melanoma, including patients 12 years or older, and in combination with Opdivo (nivolumab) for intermediate or poor-risk renal cell carcinoma, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (including patients 12 years or older), hepatocellular carcinoma previously treated with Nexavar (sorafenib), in combination with Opdivo (nivolumab) as first-line therapy in patients with PD-L1-positive (>=1%) metastatic non-small cell lung cancer without EGFR or ALK alterations, and in combination with Opdivo (nivolumab) and platinum-based chemotherapy as first-line therapy in patients with metastatic or recurrent non-small cell lung cancer without EGFR or ALK alterations (FDA.gov).|
|UV1 Telomerase peptide vaccine||UV1/hTERT Peptide Vaccine||UV1 Telomerase peptide vaccine consists of three human Telomerase (hTERT) epitopes derived from the wild-type protein, which potentially induces anti-tumor immune response (Annals of Oncology, Vol. 27, Suppl. 8, VIII11, 2016; Abs nr: 36P, PMID: 28391357).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||melanoma||not applicable||Ipilimumab + Sargramostim + UV1 Telomerase peptide vaccine||Phase I||Actionable||In a Phase I/IIa trial, UV1 Telomerase peptide vaccine combined with Yervoy (ipilimumab) and Sargramostim was well-tolerated, and resulted in a complete response and three partial responses (n=12) in metastatic melanoma patients, with a three-year overall survival of 67% (Journal of Clinical Oncology 2020 38:5_suppl, 62-62; NCT02275416).||detail...|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|